Introducing a New Approach to Diagnose and Treat Cancer Outside of US Markets
PARK CITY, UT / ACCESSWIRE / November 17, 2021 / NuView Life Sciences, Inc ("NuView", the "company"), a clinical-stage precision oncology company focusing on innovative approaches to diagnose and treat cancers establishes NuView LATAM ("NV-LATAM") in Mexico City.
Due to the COVID pandemic, many potential advances in healthcare research and development were postponed, especially clinical trials. As the healthcare system now begins to normalize, patients are returning to their healthcare practitioners and specialty doctors for routine checkups and preventative care. Healthcare companies focusing on developing innovative treatments are once again investing in their research and development efforts. Given the current worldwide concern for health, attention is also being directed on how to deliver healthcare innovation into new geographic markets.
With this backdrop, NuView has established a presence in Latin America called NV-LATAM. The purpose of NV-LATAM is to further the company's clinical trials in Mexico City to diagnose cancer and offer a targeted therapeutic approach.
NuView's lead product, NV-VPAC1™, binds directly to VPAC1 receptors that are found to be overexpressed on the surface of a variety of cancer cells. Prospective advantages include the ability to identify malignant from benign lesions, potentially lowering the chances of either a false positive or negative result, reducing patient anxiety, and decreasing the need for invasive biopsies or unnecessary medical procedures.
"NV-LATAM is introducing a modern approach to cancer identification and treatment based on molecular expressions found on the surface of cancer cells for a variety of malignancies," said Dr. Robert Maroon, Chief Executive Officer of NV-LATAM will start by submitting an in vitro genitourinary lab assay application with intent of receiving approval from COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios), Mexico's federal agency in charge of overseeing and approving medical devices. NV-LATAM believes that NuView's NV-VPAC1 will offer a novel approach to identifying cancer and hold significant benefits for patients, physicians, and the national healthcare system."
Paul Crowe, Chairman and Chief Executive Officer of NuView, remarked, "NuView's mission is to enhance the way that cancer is discovered and treated utilizing the technology invented by Dr. Mathew Thakur and later applied to liquid biopsy diagnostic applications by Dr. Mathew Thakur and Dr. Leonard Gomella at Thomas Jefferson University. Our intent is to address the patient's wellbeing as well as to assist the physicians in the sensitive task of identifying cancer and treating patients. We are especially pleased to be expanding into new markets, specifically Latin America."
NuView's NV-VPAC1 is a versatile platform technology that can potentially be utilized for preclinical and clinical studies for a variety of cancers including: brain, breast, lung, bladder, prostate, cervical, and colon. Further updates related to these additional clinical indications as well as its entry into other geographic markets will be forthcoming.
NuView's technology, branded NV-VPAC1™, consists of a small molecule peptide construct that targets the vasoactive intestinal peptide receptor type 1 (VPAC1), a part of the G protein-coupled receptor family. The VPAC1 receptor becomes highly overexpressed on the cell surface for a variety of cancers including brain, breast, lung, bladder, prostate, cervical, and colon. Attaching a molecular imaging or therapeutic passenger to NV-VPAC1 enables NuView to develop a precisely targeted approach that has been used in clinical studies for the diagnosis and treatment of cancer.
About NuView Life Sciences, Inc
NuView Life Sciences, Inc ("NuView") is a clinical-stage precision oncology company developing next-generation products to address the growing applications for radiopharmaceuticals and Theranostics in oncology. NuView's clinical stage in vivo Theranostics platform designed to deliver "paired" Copper-64 (Cu-64) and Copper-67 (Cu-67) for precision diagnosis and targeted therapy will be used for a variety of cancers found to overexpress VPAC receptors on the cell surface. The VPAC1™ receptor provides a highly-efficacious target for precision diagnosis and targeted therapeutic delivery. NuView's in vitro approach to diagnose cancer leveraging its proprietary NV-VPAC1 platform as a liquid biopsy application is labeled with a fluorophore which fluoresces on the surface of cancer cells utilizing optical imaging. This in vitro application is also under development for use as a lateral flow strip pad test. To learn more, visit https://www.nuviewlifesciences.com.
Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the development of our technology, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.
NuView Life Sciences, Inc
1389 Center Drive, Suite 200
Park City, Utah 84098
E-mail: [email protected]
Jennifer K. Zimmons, PhD, MBA
Zimmons International Communications, Inc.
E-mail: [email protected]
SOURCE: NuView Life Sciences, Inc